| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
|
Kow, Chia Siang
|
|
|
76 |
4 |
p. 361-364
|
article
|
| 2 |
Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres
|
Gras-Champel, Valérie
|
|
|
76 |
4 |
p. 369-373
|
article
|
| 3 |
COVID-19: Pharmacology has kept the science ship running during the storm
|
Molimard, Mathieu
|
|
|
76 |
4 |
p. 275-276
|
article
|
| 4 |
COVID-19 vaccines and pregnancy: What do we know?
|
Cottin, Judith
|
|
|
76 |
4 |
p. 373-374
|
article
|
| 5 |
COVID-19 vaccines: A perspective from social pharmacology
|
Montastruc, Jean-Louis
|
|
|
76 |
4 |
p. 311-315
|
article
|
| 6 |
DPP-4 inhibitors and severe course of illness in patients with COVID-19
|
Bouhanick, Béatrice
|
|
|
76 |
4 |
p. 359-360
|
article
|
| 7 |
Drug consumption during prolonged lockdown due to Covid-19 as observed in French addiction center
|
Chappuy, Mathieu
|
|
|
76 |
4 |
p. 379-382
|
article
|
| 8 |
Editorial board
|
|
|
|
76 |
4 |
p. i
|
article
|
| 9 |
Efficacy of COVID-19 vaccines: From clinical trials to real life
|
Deplanque, Dominique
|
|
|
76 |
4 |
p. 277-283
|
article
|
| 10 |
Evaluation of Covid-19 vaccines: Pharmacoepidemiological aspects
|
Pariente, Antoine
|
|
|
76 |
4 |
p. 305-309
|
article
|
| 11 |
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
|
Lacroix, Clémence
|
|
|
76 |
4 |
p. 297-303
|
article
|
| 12 |
Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
|
Gunjegaonkar, Shivshankar Malkarjun
|
|
|
76 |
4 |
p. 335-345
|
article
|
| 13 |
Médiateurs de l’inflammation : le chaînon manquant de la variabilité pharmacocinétique ?
|
Lemaitre, Florian
|
|
|
76 |
4 |
p. 317-318
|
article
|
| 14 |
Modifications pharmacocinétiques liées à une infection aiguë. Exemples issus de la pandémie de SARS-CoV-2
|
Chavant, Anaëlle
|
|
|
76 |
4 |
p. 319-333
|
article
|
| 15 |
Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19
|
Zahr, Noël
|
|
|
76 |
4 |
p. 285-295
|
article
|
| 16 |
Pneumopathie médicamenteuse ou liée à la COVID-19 : un train peut en cacher un autre !
|
Vasseur, Mélanie
|
|
|
76 |
4 |
p. 374-377
|
article
|
| 17 |
À quoi sert la licence d’office, si elle n’est pas utilisée lors d’une pandémie ?
|
Rochoy, Michaël
|
|
|
76 |
4 |
p. 377-379
|
article
|
| 18 |
Éruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19
|
Bekkali, Nihal
|
|
|
76 |
4 |
p. 364-365
|
article
|
| 19 |
Thrombotic events after AstraZeneca vaccine: What if it was related to dysfunctional immune response?
|
Billy, Eric
|
|
|
76 |
4 |
p. 367-369
|
article
|
| 20 |
Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy
|
Soeiro, Thomas
|
|
|
76 |
4 |
p. 365-367
|
article
|
| 21 |
Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19
|
Ghrieb, Zineb
|
|
|
76 |
4 |
p. 347-358
|
article
|
Journal description